AXIM Biotech Explains Cannabis Chewing Gum Clinical Trials for Pain and Spasticity With MS ...

AXIM Biotech Explains Cannabis Chewing Gum Clinical Trials for Pain and Spasticity With MS, Plans to Enter General Pain Market

NEW YORK, Aug. 20, 2015 (GLOBE NEWSWIRE) -- News of clinical trials on a new pharmaceutical cannabis chewing gum treatment option for pain and spasticity in Multiple Sclerosis (MS) patients by AXIM Biotechnologies, Inc. (OTC:AXIM) is spreading. Initial reports include: Multiple Sclerosis News Today, Marketwatch, Yahoo! Finance, Wall Street Journal, CNN Money, Marijuana Stocks Report, Culture Magazine, and Pharmacy Choice.

Yahoo! Finance's report cites, "A recent North American Research Committee on Multiple Sclerosis (NARCOMS) survey found that ...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.


URL: 
http://www.pharmiweb.com/pressreleases/pressrel.asp%3FROW_ID%3D126054